FFirmLensGLOBAL

Celltrion

068270 · KRX · Healthcare

OpenDART ↗
OpenDARTFilings checked 15 Sept 2026, 23:11 UTCFinancials checked 15 Sept 2026, 23:11 UTC

Annual reporting period: 2025-01-01 — 2025-12-31 · KRW

Annual revenue₩4.16TYear over year +17.0%
Annual net income₩1.03TConsolidated net income
Annual operating income₩1.17TConsolidated basis
Operating margin28.1%Operating income / revenue

Revenue over time

ANNUAL
2023-12-31 · 2,176,431,531,380 KRW2023₩2.18T2024-12-31 · 3,557,303,554,371 KRW2024₩3.56T2025-12-31 · 4,162,495,108,881 KRW2025₩4.16T

Each bar represents annual revenue for the fiscal year ending on the stated date. Compact amounts are rounded; exact values and filings are listed below.

Company & data

셀트리온

Healthcare

Market: South Korea
Currency: KRW
DART: 00413046

A recent filing date is not a new financial period. Annual figures may remain unchanged until the next annual report, even when new current reports are filed.

How this data is calculated →

Annual financials & sources

CONSOLIDATED
FISCAL ENDREVENUENET INCOMEOPERATING INCOMESOURCE
2025-12-31₩4.16T4,162,495,108,881 KRW₩1.03T1,031,483,789,240 KRW₩1.17T1,168,471,345,595 KRWFiling ↗
2024-12-31₩3.56T3,557,303,554,371 KRW₩418.88B418,883,310,404 KRW₩492.02B492,015,534,847 KRWFiling ↗
2023-12-31₩2.18T2,176,431,531,380 KRW₩539.71B539,706,505,110 KRW₩651.48B651,481,422,157 KRWFiling ↗
Amounts use currency-specific compact units. Exact amounts appear below each rounded value. An em dash means unavailable, not zero.

Recent official filings

OpenDART
2026-09-16DART자기주식취득결과보고서2026-09-07DART투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청 승인)2026-09-07DART투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 미국 임상 3상 시험계획 변경신청 승인)2026-08-31DART주요사항보고서(자기주식취득결정)2026-08-31DART수시공시의무관련사항(공정공시) 2026-08-28DART주식등의대량보유상황보고서(일반)2026-08-28QUARTER대규모기업집단현황공시[분기별공시(개별회사용)]2026-08-25DART풍문또는보도에대한해명(미확정) 2026-08-24DART투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 한국 품목허가 신청)2026-08-21DART임원ㆍ주요주주특정증권등소유상황보고서2026-08-14DART반기보고서 (2026.06)2026-08-14DART지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항